Antibody reactivity of a standardized human serum protein solution against a spectrum of microbial pathogens and toxins: comparison with fresh frozen plasma.

In this study, we compared a standardized solution of human serum protein (HSP) and fresh frozen plasma (FFP) with regard to the antibody specificity against a number of microbial pathogens and some important pathogenicity factors of bacterial pathogens. Due to the clinical use of HSP and FFP for therapeutical plasma exchange, we have chosen a spectrum of microbial pathogens for serological analysis that is critical in clinical settings. With the enzyme-linked immunosorbent assay technique, we could show that HSP contains marked IgG antibody reactivity against antigens of Escherichia coli, Campylobacter jejuni, Enterobacter sakazakii, Proteus mirabilis, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae, Enterococcus faecalis, Chlamydia pneumoniae, and Candida albicans. Although no IgM antibodies against the pathogens tested could be detected in HSP, moderate IgA reactivity was found against 4 of 12 microbial antigens. Immunoblot analysis demonstrated specific IgA and IgG responses against the endoproteinase Glu-C and the superantigens enterotoxin A and B of S. aureus, the IgA-protease of Neisseria gonorrhoeae, and Shiga toxin 2 of enterohemorrhagic E. coli. By using 3 different HSP batches in parallel, we could demonstrate antibody reactivity against important microbial pathogens and toxins. This antibody profile is essentially more homogeneous than that of 3 batches of FFP.

[1]  H. Peter,et al.  Comparison of fresh frozen plasma with a standardized serum protein solution following therapeutic plasma exchange in patients with autoimmune disease: a prospective controlled clinical trial. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[2]  S. Jander,et al.  Plasmapheresis in the treatment of Amanita phalloides poisoning: II. A review and recommendations. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[3]  H. Doerr,et al.  Viral Contamination of Plasma Preparations: Determination of the Prevalence of Transfusion-Transmissible Viruses (HAV, HBV, HCV, GB Virus C and HIV) in Plasma Pools and Products , 2000, Transfusion Medicine and Hemotherapy.

[4]  A. Arnold,et al.  Plasmapheresis with a substitution solution of human serum protein (5%) versus plasmapheresis with a substitution solution of human albumin (5%) in patients suffering from autoimmune diseases. , 1999, Artificial organs.

[5]  J. I. Phillips,et al.  Chlamydia pneumoniae and atherosclerosis. , 1999, JAMA.

[6]  F. Bolgert,et al.  Treatment of the adult Guillain-Barré syndrome: indications for plasma exchange. , 1999, Transfusion science.

[7]  S. Altekruse,et al.  Campylobacter jejuni--an emerging foodborne pathogen. , 1999, Emerging infectious diseases.

[8]  A. Rostami,et al.  Treatment of Guillain-Barré Syndrome with Intravenous Immunoglobulin , 1998, Neurology.

[9]  J. Mestecky,et al.  Evaluation of Immunoglobulin A1 (IgA1) Protease and IgA1 Protease-Inhibitory Activity in Human Female Genital Infection with Neisseria gonorrhoeae , 1998, Infection and Immunity.

[10]  B. Allos.  Association between Campylobacter infection and Guillain-Barré syndrome. , 1997, The Journal of infectious diseases.

[11]  M. Kilian,et al.  Inhibition of Prevotella and Capnocytophaga immunoglobulin A1 proteases by human serum , 1997, Clinical and diagnostic laboratory immunology.

[12]  H. Karch,et al.  Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations , 1995, Antimicrobial agents and chemotherapy.

[13]  J. Saurat,et al.  Characterization of two post-translationally processed forms of human serum retinol-binding protein: altered ratios in chronic renal failure. , 1995, Journal of lipid research.

[14]  T. Obrig,et al.  Hemolytic‐uremic syndrome and enterohemorrhagic Escherichia coli , 1994, The Pediatric infectious disease journal.

[15]  A. Gratwohl,et al.  [Immunoglobulin deficiency after repeated plasmapheresis]. , 1991, Schweizerische medizinische Wochenschrift.

[16]  P. Murray,et al.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis , 1989, Antimicrobial Agents and Chemotherapy.

[17]  R. Kotitschke,et al.  Serum preserve as a replacement fluid for plasma exchange therapy , 1987 .

[18]  M. Petric,et al.  Purification and biological properties of Escherichia coli verocytotoxin , 1987 .

[19]  H. Harders,et al.  Plasmapherese, Immunsuppression und hochdosierte IgG-Gaben bei chronischem Guillain-Barré-Syndrom und Antikörpern gegen peripheres Nervengewebe , 1984 .

[20]  A. Plaut,et al.  INHIBITION OF BACTERIAL IgA PROTEASES BY HUMAN SECRETORY IgA AND SERUM * , 1983, Annals of the New York Academy of Sciences.

[21]  R. Gebhardt.  Primary cultures of rat hepatocytes as a model system of canalicular development, biliary secretion, and intrahepatic cholestasis. III. Properties of the biliary transport of immunoglobulin A revealed by immunofluorescence. , 1983, Gastroenterology.

[22]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.